SISVEL
7.1.2016 17:46:21 CET | Business Wire | Press release
Sisvel, a global licensing company that has been dedicated to patent licensing since its foundation in 1982, has announced today that it is going beyond traditional patent licensing in how it acquires and monetizes patent portfolios and partners with IP players.
Sisvel is now offering its IP commercialization platform to anyone who wishes to gain greater value from Intellectual Property. This platform allows both IP Buyers and Sellers to use Sisvel’s proven network of partners, expertise in licensing and technical analysis – something no other entity now offers.
“IP buyers and sellers are in dire need to be directed by a competent player in the marketplace,” said Karel van Lelyveld, CEO of the Sisvel Group. “Sisvel has been active in this market for more than 30 years and we know what it takes to find the proverbial needle in a haystack. With our new IP Commercialization Platform we now provide easy and immediate access to buyers and sellers who want to transact assets. Our platform provides the simplicity and transparency needed to take back the market for those who develop innovative technologies and those who are seeking to get IP protection for innovative solutions”.
IP Commercialization Platform Features:
- Match for IP: Sisvel’s IP platform bridges buyer and seller requests and helps both parties achieve efficient solutions.
- Marketing IP Correctly: Sisvel’s team can help a company structure and optimize its Intellectual Property (IP) portfolio as well as identify the right assets to monetize.
- Finding the Proverbial Needle in a Haystack: Companies from around the world can now find specific IP assets in technical areas of interest, from selected sellers and pre-qualified portfolio opportunities.
“With Sisvel in the mix, there is no need to run around to ten or twenty different firms trying to buy access to the technologies you may need,” said Chuck Hausman, Vice President of Sisvel US.
Sisvel will formally unveil its new worldwide IP commercialization platform at CES 2016 with an announcement during a private reception on Thursday, January 7 from 4-6 p.m in the LVCC South Hall, Booth #1-20306. Sisvel’s management team will be available at the event to discuss the new platform’s benefits.
RSVP and further information:
Veronica Pugi veronica.pugi@sisvel.com
Sue
Ellen Schaming sschaming@hoogcomm.com
About Sisvel
Started in 1982 when Sisvel S.p.A. was founded
in Italy, the Sisvel Group has become a world leader in managing
intellectual property and maximizing the value of patent rights. The
Sisvel Group is global in scope and reach, with subsidiaries in Italy
(Sisvel and Sisvel Technology in None Torinese), the United States
(Sisvel US and Audio MPEG in Metropolitan Washington, DC), China (Sisvel
Hong Kong), Japan (Sisvel Japan in Tokyo), Germany (Sisvel Germany in
Stuttgart), Luxembourg (Sisvel International), and the United Kingdom
(Sisvel UK), with over one hundred professionals worldwide with
engineers, legal, and licensing expertise. Sisvel has a long history of
managing successful patent portfolios including those related to the
audio compression standards known as MP3 and MPEG Audio, and widespread
technologies such as OSD (On Screen Display), ATSS (Automatic Tuning &
Sorting System), and WSS (Wide Screen Signalling - for automatic
switching of television image formats). Sisvel currently operates patent
pools and joint licensing programs for the DVB-T, DVB-T2, LTE/LTE-A and
Wi-Fi standards, together with its Sisvel Wireless licensing program and
is in the process of creating a new licensing program for DVB-C2.
For additional information, please visit: www.sisvel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005959/en/
Contact:
Media Contact
Sisvel Group
Veronica Pugi, Tel: +
39 011 990 4114
Senior Communications Officer
veronica.pugi@sisvel.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom